urofollitropin (puregon, serono, organon, FSH-beta, Fertinex, Metrodin, Bravelle)
Jump to navigation
Jump to search
Introduction
Tradenames: Bravelle
Indications
- induction of ovulation in patients with polycystic ovarian disease
- stimulation of development of multiple oocytes
- infertility in women with proven hypopituitarism or who have not responded to clomifene
- superovulation treatment for assisted conception (such as in vitro fertilization)
- Metrodin HP is also used in the treatment of hypogonadotrophic hypogonadism in men for the stimulation of spermatogenesis
Contraindications
Dosage
Powder for injection: 75 IU of FSH (0.83 mg, 2 mL)
Adverse effects
- common (> 10%)
- ovarian enlargement, swelling at site of injection, pain
- less common (1-10%)
- hyperstimulation syndrome, fever/chills, rash, abdominal pain, diarrhea, arterial thromboembolism, nausea/vomiting
Mechanism of action
More general terms
Additional terms
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ Drugs.com http://www.drugs.com/mtm/urofollitropin.html